Richard Peters
Independent Chairperson of the BoardDr. Richard Peters, M.D., Ph.D., is a Founder at X4 Pharmaceuticals, Inc. and previously served as its Director. He serves as Non-Executive Chairman of Board & Non-Executive Director of Pharming Group N.V. since September 25, 2023. Dr. Peters was Co-Founder, President, Treasurer, Secretary & Director of TellBio, Inc. until November 2025. Dr. Peters was President, Treasurer, Secretary & Executive Director of TellBio, Inc. Dr. Peters was Executive Director of TellBio, Inc. Dr. Peters is Co-Founder, Executive Chairman, President, Treasurer & Secretary of TellBio, Inc. from November 2025. He has been an Independent Director of Aprea Therapeutics, Inc. since June 30, 2020 and as its Chairperson of the Board from August 23, 2023. He served as Lead Independent Director at Kineta, Inc. since December 26, 2022 until June 30, 2025. He serves as Independent Director at Aprea Therapeutics AB since July 2020. He served as Director of PIC Therapeutics Inc. He Co-Founded PIC Therapeutics Inc. Dr. Peters served as Chief Executive Officer, President and Director at Yumanity Therapeutics Inc. since September 2019 to December 2022 and served as its Treasurer and Secretary. He has served as the President, Chief Executive Officer and a Member of the Board of Directors of Yumanity, Inc. since September 2019. Dr. Peters served as Scientific and Clinical Advisor at Aura Biosciences, Inc. Dr. Peters served as the Chief Executive Officer and President of Merrimack Pharmaceuticals, Inc. since February 6, 2017 until June 28, 2019 and served as its Principal Financial Officer from June 2017 to August 21, 2017. Dr. Peters is a Harvard-trained physician-scientist. He has years of biotech (oncology and specialty care) experience including roles of increasing responsibility in medical affairs at Onyx Pharmaceuticals, Inc. and Amgen Inc. He served as Global Head of Rare Diseases and Senior Vice President at Genzyme Corporation (Sanofi Genzyme) from April 2014 to January 2017 and served as its Vice President. He joined Genzyme in 2008. He oversaw a portfolio of products that serves patients in more than 90 countries worldwide. He was a co-Founder of Mednav, Inc. and served as its Chief Executive Officer. Dr. Peters served in various capacities at Sanofi Genzyme, a global pharmaceutical company, since 2008, including as Senior Vice President, Head of Global Rare Diseases Business Unit since January 2015, Vice President, Strategy Development Officer, U.S. Rare Disease Unit from May 2014 to December 2014, Vice President, Division Medical Officer, Global Oncology Division from 2011 to May 2014 and Vice President, Head of Global and U.S. Medical Affairs, Hematology and Transplant from 2008 to 2011. He served as Deputy Head for the Genzyme Global Rare Diseases Division at Genzyme Therapeutic Products Limited Partnership. He served as Senior Director of Medical Affairs at Onyx Pharmaceuticals. He served as Director of Medical Affairs at Amgen Inc. He served as a Director of Merrimack Pharmaceuticals, Inc. since February 6, 2017 until June 28, 2019. Dr. Peters has served on the faculty/clinical staff at Harvard Medical School/Massachusetts General Hospital in Boston. He began his medical training at the Université Catholique de Louvain in Brussels, Belgium. He has served as a consulting editor for JAMA and as a contributing editor for Science and has authored over 120 research articles and editorials. Dr. Peters earned his M.D. and Ph.D. in Pharmacology from the Medical University of South Carolina and a B.S. from the College of Charleston. He completed postgraduate training at Massachusetts General Hospital and a Howard Hughes Medical Institute Fellowship in biophysics at Harvard Medical School. Dr. Peters was Co-Founder, President, Treasurer, Secretary & Director of TellBio, Inc. until November 2025. Dr. Peters was President, Treasurer, Secretary & Executive Director of TellBio, Inc. Dr. Peters was Executive Director of TellBio, Inc. Dr. Peters is Co-Founder, Executive Chairman, President, Treasurer & Secretary of TellBio, Inc. from November 2025.
Positions
- Company NameAprea Therapeutics, Inc.Stock CodeAPREPositionIndependent Chairperson of the BoardColleagues
- OGOren GiladCo-Founder, CEO, President & Director
- JPJohn P. HamillSenior VP, CFO, Principal Accounting Officer & Secretary
- LBLars B. AbrahmsenSenior VP & Chief Scientific Officer
- BWBrian WileySenior Vice President of Corporate Development & Strategy
- MAMichel AfarganHead of Pharmacology Development
- MJMichael J. GrissingerIndependent Director
- JBJohn B. HennemanIndependent Director
- RPRifat PamukcuIndependent Director
- Company NameX4 Pharmaceuticals, Inc.Stock CodeXFORPositionFounderColleagues
- ARAdam R. CraigExecutive Chair
- JPJohn P. VolponePresident & COO
- DHDavid H. KirskeCFO, Treasurer & Corporate Secretary
- RPRichard PetersFounder
- RTRenato T. SkerljFounder
- KTKeith T. FlahertyFounder & Member of Corporate Advisory Board
- MSMichael Stephen WyzgaLead Independent Director
- MWMurray W. StewartDirector
- MJMichael J. VasconcellesMember of Corporate Advisory Board
- Company NamePharming Group N.V.Stock CodePHARPositionNon-Executive Chairman of BoardColleagues
- KLKenneth LynardCFO & Co-Chief Executive Officer
- RPRichard PetersNon-Executive Chairman of Board
- LMLeverne MarshCo-CEO & Chief Commercial Officer
- MSMireille SandersChief Operations Officer
- MKMichael K. LevitanVP of Investor Relations & Corporate Communications
- RVRuud Van OutersterpChief Legal & Compliance Officer and Company Secretary
- MJMark Jerome PykettIndependent Non-Executive Vice Chairman
- JTJabine T. M. van der MeijsIndependent Non-Executive Director
- LKLeonard KruimerIndependent Non-Executive Director
- ESElaine SullivanNon Executive Director
